As for the genetic landscape in detail, several incidences of mutated genes that were adverse to prognosis were observed to be lower in the young lung cancer group (LRP1B, SMARCA4, STK11, FAT2, RBM10, FANCM), which may explain the better prognosis of the young lung cancer group to some extent. This evidence concerns the gene FAT2 and lung carcinoma.